Early response assessment to targeted therapy in metastatic clear cell renal cancer using 68Ga-PSMA-11 PET/CT and comparison with CECT: a feasibility study

ConclusionEarly response assessment with68Ga-PSMA-11 PET/CT is feasible and provides more accurate prognostic information than CECT in metastatic clear cell RCC patients undergoing targeted therapy.Trial registration numberCTRI/2021/05/033805 (date of registration: 25/05/21)
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research